Wellcome's fourth conference on the Genomics of Brain Disorders.
This meeting will bring together international scientists and clinicians working on neurodegenerative and psychiatric diseases to compare approaches used and the emerging lessons from both categories of disease.
Psychiatric disorders, such as schizophrenia and depression, and neurodegenerative disorders, such as Alzheimer’s disease and Parkinson’s disease, are placing an increasing burden on the developed world. Technical advances over the past few years, including genome-wide association and next-generation sequencing studies, have led to the discovery of many predisposing loci for both psychiatric and neurodegenerative disorders.
The conference will synthesise these advances and challenges in the genomics of various brain disorders. This year’s programme will explore recent insights into complex variations and genetic architecture in these disorders. We will also include sessions to discuss emerging tools and technologies, including functional assays, long-read sequencing, single cell, organoids, and other modelling approaches. In addition, we will highlight the methods used in population studies and how genomics is driving new therapeutics.
This conference will be a hybrid meeting – with onsite or virtual attendance.
If you would like to be part of these discussions – consider submitting an abstract by 21 March 2023 and register by 18 April (in-person) or 9 May (virtual) 2023.
To promote more inclusive scientific discussions with international colleagues at our conferences, virtual delegates based in Lower and Middle-Income Countries can register for free.
